Qualitative and Quantitative Analysis of DNA Cytidine Deaminase Activity.
AID
APOBEC
Cytidine deaminase
DNA base editors
Deaminase
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
15
3
2022
pubmed:
16
3
2022
medline:
18
3
2022
Statut:
ppublish
Résumé
The human genome encodes eleven DNA cytidine deaminases in the AID/APOBEC family, which encompass endogenous roles ranging from genetic diversification of the immunoglobulin locus to virus restriction. All AID/APOBEC functions are enabled by their catalyzation of cytidine deamination resulting in mutations and DNA damage. When acting aberrantly, deaminases can cause off-target mutations in the cellular genome resulting in somatic mutations, DNA damage, and genome instability. An association between cytidine deaminase-induced mutations and human cancers has been recognized over the last decade, necessitating assays for investigation of intracellular deaminase activity. Here we present two assays for deamination activity which enable in vitro evaluation of in vivo events. We define both a qualitative assay to confirm deaminase activity within cells as well as a quantitative assay for granular evaluation and comparisons of deamination activity across different cell populations or experimental conditions. The two procedures are customizable assays which can easily be adapted to individual labs and experiments.
Identifiants
pubmed: 35290637
doi: 10.1007/978-1-0716-2063-2_10
doi:
Substances chimiques
DNA
9007-49-2
APOBEC Deaminases
EC 3.5.4.5
Cytidine Deaminase
EC 3.5.4.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-169Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Casellas R, Basu U, Yewdell WT, Chaudhuri J, Robbiani DF, Di Noia JM (2016) Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity. Nat Rev Immunol 16(3):164–176. https://doi.org/10.1038/nri.2016.2
doi: 10.1038/nri.2016.2
pubmed: 26898111
pmcid: 4871114
Green AM, Weitzman MD (2019) The spectrum of APOBEC3 activity: from anti-viral agents to anti-cancer opportunities. DNA Repair (Amst) 83:102700. https://doi.org/10.1016/j.dnarep.2019.102700
doi: 10.1016/j.dnarep.2019.102700
Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS (2013) DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. elife 2:e00534. https://doi.org/10.7554/eLife.00534
doi: 10.7554/eLife.00534
pubmed: 23599896
pmcid: 3628087
Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 16(5):480–485. https://doi.org/10.1016/j.cub.2006.01.031
doi: 10.1016/j.cub.2006.01.031
pubmed: 16527742
Okazaki I, Yoshikawa K, Kinoshita K, Muramatsu M, Nagaoka H, Honjo T (2003) Activation-induced cytidine deaminase links class switch recombination and somatic hypermutation. Ann N Y Acad Sci 987:1–8. https://doi.org/10.1111/j.1749-6632.2003.tb06027.x
doi: 10.1111/j.1749-6632.2003.tb06027.x
pubmed: 12727618
Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424(6944):99–103. https://doi.org/10.1038/nature01709
doi: 10.1038/nature01709
pubmed: 12808466
Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113(6):803–809. https://doi.org/10.1016/s0092-8674(03)00423-9
doi: 10.1016/s0092-8674(03)00423-9
pubmed: 12809610
Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, Logue E, Landau NR, Weitzman MD (2009) Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog 5(5):e1000439. https://doi.org/10.1371/journal.ppat.1000439
doi: 10.1371/journal.ppat.1000439
pubmed: 19461882
pmcid: 2678267
Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, DJ MB, Bignell GR, Cooke SL, Shlien A, Gamble J, Whitmore I, Maddison M, Tarpey PS, Davies HIR, Papaemmanuil E, Stephens PJ, McLaren S, Butler AP, Teague JW, Jonsson G, Garber JE, Silver D, Miron P, Fatima A, Boyault S, Langerod A, Tutt A, Martens JW, Aparicio SA, Borg A, Salomon AV, Thomas G, Borresen-Dale AL, Richardson AL, Neuberger MS, Futreal PA, Campbell PJ, Stratton MR, Breast Cancer Working Group of the International Cancer Genome Consortium (2012) Mutational processes molding the genomes of 21 breast cancers. Cell 149(5):979–993. https://doi.org/10.1016/j.cell.2012.04.024
doi: 10.1016/j.cell.2012.04.024
pubmed: 22608084
pmcid: 3414841
Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, Getz G, Gordenin DA (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45(9):970–976. https://doi.org/10.1038/ng.2702
doi: 10.1038/ng.2702
pubmed: 23852170
pmcid: 3789062
Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg AL, Cunningham JM, Shridhar V, Bell DA, April C, Bentley D, Bibikova M, Cheetham RK, Fan JB, Grocock R, Humphray S, Kingsbury Z, Peden J, Chien J, Swisher EM, Hartmann LC, Kalli KR, Goode EL, Sicotte H, Kaufmann SH, Harris RS (2013) APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res 73(24):7222–7231. https://doi.org/10.1158/0008-5472.CAN-13-1753
doi: 10.1158/0008-5472.CAN-13-1753
pubmed: 24154874
Schutsky EK, Nabel CS, Davis AKF, DeNizio JE, Kohli RM (2017) APOBEC3A efficiently deaminates methylated, but not TET-oxidized, cytosine bases in DNA. Nucleic Acids Res 45(13):7655–7665. https://doi.org/10.1093/nar/gkx345
doi: 10.1093/nar/gkx345
pubmed: 28472485
pmcid: 5570014
Thielen BK, McNevin JP, McElrath MJ, Hunt BV, Klein KC, Lingappa JR (2010) Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem 285(36):27753–27766. https://doi.org/10.1074/jbc.M110.102822
doi: 10.1074/jbc.M110.102822
pubmed: 20615867
pmcid: 2934643
Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, Kwiatkowski DJ, Fargo DC, Mieczkowski PA, Getz G, Gordenin DA (2015) An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet 47(9):1067–1072. https://doi.org/10.1038/ng.3378
doi: 10.1038/ng.3378
pubmed: 26258849
pmcid: 4594173